Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

177Lu-PSMA-617

Novartis building

Novartis charged in Japan over data falsification

Prosecutors claim pharma company employees manipulated Diovan data

Novartis building

Novartis pulls EMA application for expanded Tasigna use

And Boehringer confirms it won't seek approval for faldaprevir as it exits hepatitis C

- PMLiVE

Novartis and NHS launch mobile eye unit in UK

First of its kind unit to offer 250 clinic slots per week across Surrey, Hampshire and Berkshire

- PMLiVE

Takeda drops prostate cancer drug in phase III

Suffers another late-stage pipeline blow as orteronel disappoints

- PMLiVE

Bruno Strigini leaves Merck & Co for Novartis

Will head up an oncology business boosted by the acquisition of GSK's portfolio

- PMLiVE

Novartis appoints new comms chief

Michael Willi replaces Michele Galen

- PMLiVE

Novartis, Boehringer stake claims to combination COPD market

Includes combination follow-up to Spiriva

Novartis day

Novartis licenses Ophthotech eye drug in $1bn deal

Fovista is a potential first-in-class treatment for wet AMD

Novartis building

FDA rejects Novartis’ breakthrough heart failure drug

Regulator wants more data on serelaxin

- PMLiVE

NICE won’t back early use of Zytiga in prostate cancer

Says Janssen drug should not be used prior to chemotherapy

National Institute for Health and Care Excellence NICE logo

NICE backtracks on prostate cancer drug enzalutamide

Says Astellas and Medivation's Xtandi can be used within the NHS in England and Wales

Novartis building

Novartis plans filings for acromegaly candidate

Could add to Signifor’s indications

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links